^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD3 agonist

    Related drugs:
    4d
    SOUNDTRACK-D2: AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL (clinicaltrials.gov)
    P3, N=420, Recruiting, AstraZeneca
    Trial initiation date
    |
    doxorubicin hydrochloride • cyclophosphamide • surovatamig (AZD0486)
    5d
    A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101) (clinicaltrials.gov)
    P1, N=100, Recruiting, MSD R&D (China) Co., Ltd. | Trial primary completion date: Mar 2027 --> Sep 2028
    Trial primary completion date
    |
    IL2 (Interleukin 2)
    |
    CD19 positive
    6d
    Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients (clinicaltrials.gov)
    P1, N=33, Completed, Arbele Pty Ltd | Recruiting --> Completed | N=68 --> 33 | Trial completion date: May 2026 --> Jul 2025 | Trial primary completion date: Mar 2026 --> Jul 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • First-in-human
    |
    CDH17 (Cadherin 17)
    |
    Tecentriq (atezolizumab) • cabotamig (ARB202)
    6d
    Efficacy and Safety of SBRT Combined With Becotatug Vedotin in EGFR-Positive Metastatic Tumor Patients With Oligometastases (clinicaltrials.gov)
    P3, N=200, Not yet recruiting, Ming-Yuan Chen
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin) • becotarug (JMT101) • vibecotamab (XmAb14045)
    6d
    UPCC 48420: CAR-T Followed by Bispecific Antibodies (clinicaltrials.gov)
    P2, N=42, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Jun 2027 --> Dec 2028 | Trial primary completion date: Jun 2026 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Gazyva (obinutuzumab) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)
    6d
    Efficacy and Safety of Glofitamab Combined With GemOxin the Treatment of Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
    New P2 trial
    |
    gemcitabine • Gazyva (obinutuzumab) • oxaliplatin • Columvi (glofitamab-gxbm)
    7d
    CLLRT2: A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with DLBCL-type Richter Transformation (2024-513445-37-00)
    P2/3, N=41, Not yet recruiting, University Of Cologne
    New P2/3 trial
    |
    Rituxan (rituximab) • cyclophosphamide • pegylated liposomal doxorubicin • vincristine • Jaypirca (pirtobrutinib) • Epkinly (epcoritamab-bysp)
    7d
    SKYGLO: An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=1130, Active, not recruiting, Hoffmann-La Roche | Trial primary completion date: Dec 2027 --> Oct 2027
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • prednisone • Polivy (polatuzumab vedotin-piiq) • Columvi (glofitamab-gxbm)
    7d
    International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) (clinicaltrials.gov)
    P3, N=750, Not yet recruiting, Charite University, Berlin, Germany
    New P3 trial
    |
    CD22 (CD22 Molecule)
    |
    CD19 positive • CD22 positive
    |
    Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
    7d
    IMCgp100-202: Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma (clinicaltrials.gov)
    P2, N=378, Completed, Immunocore Ltd | Active, not recruiting --> Completed
    Trial completion
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • dacarbazine • Kimmtrak (tebentafusp-tebn)
    8d
    ELEVATE-1: A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD) (clinicaltrials.gov)
    P1, N=54, Recruiting, GlaxoSmithKline | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GSK5926371
    8d
    Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies (clinicaltrials.gov)
    P1, N=61, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jun 2028 --> May 2026 | Trial primary completion date: Jun 2027 --> May 2026
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    PIT565